Related references
Note: Only part of the references are listed.Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy
Katsuhiro Miura et al.
LEUKEMIA & LYMPHOMA (2016)
Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma
Daisuke Kurita et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome
Gabriel C. Caponetti et al.
LEUKEMIA & LYMPHOMA (2015)
Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era
Chieh-Sheng Lu et al.
LEUKEMIA & LYMPHOMA (2015)
Alternative intensive induction chemotherapeutic regimens in MYC expressing diffuse large B-cell lymphoma
Judy P. Tsai et al.
LEUKEMIA & LYMPHOMA (2015)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou et al.
BLOOD (2014)
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Adam M. Petrich et al.
BLOOD (2014)
Double hit lymphoma: the MD Anderson Cancer Center clinical experience
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B
Thierry Jo Molina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma
Yujin Kobayashi et al.
LEUKEMIA & LYMPHOMA (2014)
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Heike Horn et al.
BLOOD (2013)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Patrick J. Stiff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Norbert Schmitz et al.
LANCET ONCOLOGY (2012)
An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma
Katsuhiro Miura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement
Keun-Wook Lee et al.
ANNALS OF HEMATOLOGY (2009)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue
Roland A. Ventura et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2006)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Dose-intensified CHOP (double-CHOP) followed by consolidation with high-dose chemotherapy for high and high-intermediate risk aggressive non-Hodgkin's lymphomas
T Yamazaki et al.
LEUKEMIA & LYMPHOMA (2002)
Share Paper
